Helsinn Presents Quality of Life, Its First Group Sustainability Report - European Medical Journal

Helsinn Presents Quality of Life, Its First Group Sustainability Report

Lugano, Switzerland, March 23, 2016: Helsinn Group is pleased to present its first group sustainability report, Quality of Life, demonstrating that being a good corporate citizen is at the heart of everything we do.

Quality of Life was prepared in accordance with the Global Reporting Initiative guidelines. GRI provides a Sustainability Reporting framework which is universally recognized as the most comprehensive global standard for sustainability reporting, allowing companies to set goals, measure performance and manage change. A sustainability report discloses the full range of an organization’s impacts on society, the environment and the economy.

Quality of Life provides detailed assessments of how the group’s operations, from R&D to supply chain to management, impacts on these stakeholders, including patients, staff, the wider community and the environment. It covers all of Helsinn’s operating subsidiaries.

Helsinn this year celebrates its 40th anniversary, reflecting on its core values of quality, integrity and respect. Since its foundation in 1976, Helsinn has always believed that long-term, sustainable commercial success is linked to operating in a way which benefits the needs of our stakeholders, the wider community and the environment. Now, for the first time, we are able to measure our success against these guiding principles as we strive to improve them.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO, comments: “Helsinn is a family company and respect, integrity and quality are at the heart of everything we do. We believe that our obligations to our stakeholders, employees and the community we operate in, and stewardship of our environment, are as important as our commercial and financial success”.

Giorgio Calderari, Group General Manager, comments: Quality of Life was a challenging, but fascinating and very rewarding document to produce. It has given us a foundation upon which to build a sustainability strategy.

We have got very valuable feedback through this process: we now have a thorough understanding of what our goals are and how we can achieve them. We have been delighted at the positive response from our staff and their engagement with the need for sustainability, and wish to thank everyone who participated in the production of this report.

As we move forward towards our goal of making our organization ever more responsive to the need for accountability to all stakeholders, we urge all at Helsinn to embrace this progress.”

 

For a full copy of the report, please visit:http://www.helsinn.com/responsibility/sustainability/

About the Helsinn Group
Helsinn is a privately owned cancer supportive care pharmaceutical group with an extensive portfolio of marketed products and a broad development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality, through a unique integrated licensing business model working with long standing partners in pharmaceuticals, medical devices and nutritional supplement products. Helsinn is headquartered in Lugano, Switzerland, with operating subsidiaries in Ireland and the US, a representative office in China, as well as a product presence in about 90 countries globally.

In 2016, our 40th anniversary year, you can meet representatives from Helsinn at:

  • NCCN Annual Conference (Hollywood, FL, USA, 31 March-2 April)
  • ASCO Annual Meeting (Chicago, USA, 3-7 June)
  • MAASC Annual Meeting (Adelaide, Australia, 23-25 June)
  • ChemOutsourcing Conference (Parsippany, New Jersey, 19-21 September)
  • CPhI Worldwide (Barcelona, Spain, 4-6 October)
  • ESMO Congress (Copenhagen, Denmark, 7-11 October)
  • BioEurope (Köln, Germany, 4-6 November)

For more information, please visit www.helsinn.com.

For further information please contact:
Helsinn Group
Paola Bonvicini
Head of Communication & Press Office
PH +41 91-985-21-21
[email protected]

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.